Secarna Pharmaceuticals GmbH & Co. KG
/ Key word(s): Miscellaneous
Secarna Pharmaceuticals and Curie Expand Existing Partnership
03.03.2026 / 09:00 CET/CEST
The issuer is solely responsible for the content of this announcement.
Secarna Pharmaceuticals and Curie Expand Existing Partnership
Expansion of existing scientific and strategic collaboration agreement announced in May 2025
Secarna to support Curie in identifying oligonucleotide candidates for its company ventures Martinsried (Munich), Germany, March 3, 2026 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics today announced the expansion of the existing scientific and strategic collaboration agreement with Curie announced in May 2025. The expansion includes Secarna's support in identifying oligonucleotide candidates using its proprietary OligoCreator® platform for research and development projects conducted by Curie portfolio companies.
“The decision to expand our cooperation serves as validation of our fruitful partnership with Curie so far,” said Konstantin Petropoulos, PhD, CEO of Secarna Pharmaceuticals.“It shows a high level of trust between our teams who excellently work together to discover and develop new therapies against difficult to treat diseases. Our shared vision of transforming scientific innovation into life-changing therapies guides our daily work, driving us to efficiently generate measurable results in discovering and developing best-in-class drug products.”
Secarna's AI-empowered OligoCreator® platform seamlessly integrates diverse delivery technologies as well as proprietary safety and efficacy testing systems to identify and characterize oligonucleotide therapeutics with exceptional speed, safety, and efficacy – strengthening its position as a pivotal tool in transforming previously untreatable conditions into treatable ones and profoundly shaping the future of medicine.
About Secarna Pharmaceuticals
Secarna Pharmaceuticals is a biopharmaceutical company redefining the discovery and development of best-in-class oligonucleotide therapeutics, offering hope to patients facing conditions that are beyond the reach of current approaches and modalities. With the Company's proprietary AI-empowered OligoCreator® platform, which includes multiple delivery technologies, Secarna identifies and characterizes oligonucleotide therapeutics with unparalleled speed and excellent safety and efficacy. By delivering these novel therapeutics to the cells, organs, or tissues where they are needed, targeted oligonucleotide therapies have the potential to revolutionize treatments for a wide range of difficult-to-treat disorders. Secarna's unique OligoCreator® platform is leveraged to transform untreatable conditions into treatable ones, profoundly changing the future of medicine.
About Curie
Curie is a $1.25B global venture capital firm that helps founders discover and develop important new medicines. The firm partners with founders by investing in existing companies, creating focused spinouts, and building companies from scratch. Curie's model uniquely combines capital with hands-on drug development, operating as both a drug discovery copilot and an investor. Its 100+ person team of experienced drug hunters, drug makers, and operators works closely with founders on a day-to-day basis to improve decision-making and increase the probability of success. Curie helps founders avoid critical early mistakes and ensures they have the right scientific plan, data package, and narrative to maximize long-term value creation. Curie invests across the lifecycle of therapeutic development, from preclinical discovery through clinical proof-of-concept. Learn more at
Contact
Secarna Pharmaceuticals GmbH & Co. KG
Konstantin Petropoulos, PhD, MBA
CEO
Phone: +49 (0)89 215 46 375
Email: ...
Secarna Pharmaceuticals
For media inquiries
MC Services AG
Anne Hennecke/Lydia Robinson-Garcia
Phone: +49 (0)211 52 92 52 15
Email: ...
03.03.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|
2284124 03.03.2026 CET/CEST
MENAFN03032026004691010666ID1110809763
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Comments
No comment